Who is sponsoring NCT03750175?

NCT03750175 is sponsored by Karen-Lise Garm Spindler.

What drugs are being tested in NCT03750175?

Interventions in NCT03750175: Plasma circulating DNA analysis.

What condition does NCT03750175 study?

NCT03750175 studies Colorectal Cancer Metastatic, Circulating Tumor DNA, KRAS Gene Mutation, NRAS Gene Mutation, BRAF Gene Mutation, Epidermal Growth Factor Receptor Inhibitor.

Is NCT03750175 still recruiting?

NCT03750175 is currently completed. Last updated 3 February 2023.

Last reviewed 2023-02-03 · How we verify

NCT03750175: OPTIPAL-II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Completed Last updated 3 February 2023

What this trial tests

trial testing Plasma circulating DNA analysis in Colorectal Cancer Metastatic in 49 participants. Completed in 31 December 2022.

Timeline

1 June 2018

Primary endpoint
1 June 2022

31 December 2022

Quick facts

Lead sponsor	Karen-Lise Garm Spindler
Status	Completed
Study type	OBSERVATIONAL
Enrollment	49
Start date	1 June 2018
Primary completion	1 June 2022
Estimated completion	31 December 2022
Sites	1 location across Denmark

Drugs / interventions tested

Plasma circulating DNA analysis

Conditions studied

Colorectal Cancer Metastatic — all drugs for Colorectal Cancer Metastatic →
Circulating Tumor DNA — all drugs for Circulating Tumor DNA →
KRAS Gene Mutation — all drugs for KRAS Gene Mutation →
NRAS Gene Mutation — all drugs for NRAS Gene Mutation →

Sponsor

Karen-Lise Garm Spindler — full company profile →

Who can join

18 and older, any sex, with Colorectal Cancer Metastatic or Circulating Tumor DNA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA.
Patelli G, Vaghi C, Tosi F, Mauri G, et al · · 2021 · cited 27× · PMID 33738696 · DOI 10.1007/s11523-021-00795-5
Total cell-free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay.
Callesen LB, Sørensen BS, Pallisgaard N, Laugesen IG, et al · · 2022 · cited 2× · PMID 35154704 · DOI 10.3892/mco.2022.2497

Verify or expand the search:

Other recruiting trials for Colorectal Cancer Metastatic

Currently open trials in the same condition.

NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
NCT07462650 — Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer · Phase 1, PHASE2 · recruiting
NCT07193862 — Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Meta · EARLY_PHASE1 · recruiting
NCT07172282 — INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases · EARLY_PHASE1 · recruiting
NCT06889610 — A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. · Phase 2 · recruiting

Other Karen-Lise Garm Spindler trials

Trials by the same sponsor.

NCT06562348 — The ctDNA-RECIST Trial Part One · Phase 2 · recruiting
NCT04680260 — OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer · Phase 2 · recruiting
NCT05385250 — Bone-sparing Chemoradiotherapy for Anal Cancer - DACG-II · NA · active not recruiting
NCT03748680 — IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postop · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03750175 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karen-Lise Garm Spindler
Last refreshed: 3 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03750175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing